Sermo Barometer Finds Nearly Half of Physicians Report Patients Are Using Non-FDA Regulated Peptides

Key Takeaways

• 48% of physicians report patients using non‑FDA peptides last year
• 81% want clear FDA approval pathway for emerging peptide therapies
• 84% say patients learn about peptides from social media influencers
• 69% of specialists anticipate strong patient interest in GLP‑3 agents
• 66% of doctors are concerned about unsupervised peptide use outside trials

Pulse Analysis

The surge in unregulated peptide use reflects a broader shift in consumer health, where patients bypass traditional medical channels in favor of quick‑fix solutions marketed on social platforms. Influencers and online forums have become the de‑facto educators, prompting 84% of physicians to report that patients arrive with preconceived expectations. This dynamic not only erodes the physician‑patient trust bond but also creates a data vacuum on safety and efficacy, as many of these compounds lack rigorous clinical testing.

Regulators now face mounting pressure to delineate a transparent approval pathway for peptide therapeutics. With 81% of surveyed doctors calling for clear FDA guidance, the upcoming advisory committee in July could set precedents that balance innovation with patient protection. Physicians’ chief concerns—unsupervised self‑prescribing and difficulty monitoring adverse events—underscore the need for structured clinical trials and post‑market surveillance mechanisms that can keep pace with rapid market entry.

Looking ahead, the market is poised for a transition from GLP‑1 to next‑generation GLP‑3 agents, which 69% of specialists expect to drive strong demand. The anticipated rollout of triple‑agonist drugs like retatrutide could reshape metabolic care, attracting both patients seeking weight loss and investors chasing high‑growth biotech opportunities. Companies that align product development with clear regulatory pathways and robust physician education stand to capture a sizable share of the expanding wellness economy, while mitigating the risks associated with the current “wild west” of peptide use.